Unlearn.AI Website, Blog & Press Pages

Unlearn.AI Website, Blog & Press Pages - aVenture

Unlearn.AI - Library

unlearn.aiCrawled Oct 15, 2026

Blog

6 pages

2025: Proving How Purpose-Built AI Moves the Needle in Clinical Development/blog/2025-proving-how-purpose-built-ai-moves-the-needle-in-clinical-development
Clinical development is complex and expensive. The company aims to help teams design studies, align more quickly, and make decisions with greater clarity.
Accelerating Clinical Innovation in Crohn’s Disease with AI/blog/accelerating-clinical-innovation-in-crohns-disease-with-ai
The company announced the release of a Digital Twin Generator for Crohn’s disease, an inflammatory bowel disease.
AD Model Update: AD DTG 4.2 — Exploring Biomarker Outcomes in Alzheimer's Disease/blog/ad-model-update-ad-dtg-4-2-exploring-biomarker-outcomes-in-alzheimers-disease
The release expands the biomarker data available to the model and enables early exploration of biomarkers as potential clinical outcomes.
AI in drug development/blog/advancements-in-digital-twin-generators-a-leap-forward-in-inflammation-and-immunology-research
The company has created digital twin generators for rheumatoid arthritis, plaque psoriasis, and atopic dermatitis.

Press

1 page

Press/press
Unlearn's page features news, press releases, media coverage, and information about its AI-powered solutions for clinical trials.

Careers & Hiring

1 page

Careers/careers
Unlearn offers career opportunities in AI for clinical trials and digital twin technology for clinical development.

Team

6 pages

Aaron Smith, Founder & Head of AI at Unlearn/team/aaron-smith
Meet Unlearn founder Aaron Smith, a mathematician with research interests in computer vision, machine learning, physics, and geometry.
Andrew Stelzer, Head of Business Development at Unlearn/team/andrew-stelzer
Meet Unlearn Head of Business Development Andrew Stelzer, a business development expert in the biotechnology and pharmaceutical industries.
Ann Taylor, former CMO at AstraZeneca/team/ann-taylor
Ann Taylor is a Unlearn board member and former Chief Medical Officer at AstraZeneca, responsible for global Patient Safety, Quality Assurance, Regulatory Policy, and benefit-risk assessment of medicines.
Charles K. Fisher, founder of Unlearn/team/charles-k-fisher
Meet Unlearn founder Charles K. Fisher, a scientist with interests at the intersection of physics, AI, and computational biology.

About

1 page

About/about
Unlearn pioneers AI-driven solutions for clinical trials with digital twins of trial participants that streamline clinical development and will eliminate trial and error in medicine tomorrow.

Homepage

1 page

Homepage/
Unlearn uses AI to create digital twins of clinical trial participants for clinical development and decision-making.

Privacy

1 page

Privacy/privacy
Unlearn.AI's privacy page describes how it collects, uses, and protects information and outlines its data practices and user choices.

Terms & Conditions

1 page

Terms/terms
Unlearn.AI's Terms of Service describe rights and responsibilities for using its website and services, including access, use, and legal agreements.

Coverage

6 items

Unlearn to Support SOLA Biosciences' Clinical Study Using AI-Generated Digital Twinsnewswire.com/news/unlearn-to-support-sola-biosciences-clinical-study-using-ai-generated-22740174
Unlearn will support SOLA Biosciences' early-phase study of SOL-257 by generating participant-level digital twins as prespecified external comparators. SOL-257 is an investigational gene therapy for amyotrophic lateral sclerosis. The engagement covers trial planning, regulatory support, and long-term follow-up for the study.
Mar 2026 · Newswire.comNews article
Unlearn to Apply AI-Generated Digital Twins to the VectorY Therapeutics PIONEER-ALS Studynewswire.com/news/unlearn-to-apply-ai-generated-digital-twins-to-the-vectory-22726468
Unlearn collaborates with VectorY Therapeutics on its early-phase PIONEER-ALS study of VTx-002, a vectorized antibody targeting TDP-43 pathology in amyotrophic lateral sclerosis. Unlearn’s ALS Digital Twin Generator produces participant-level forecasts of outcomes under standard care, which serve as external comparators in the single-arm design.
Feb 2026 · Newswire.comNews article
unlearnaigithub.com/unlearnai
GitHubRepository owner
Unlearn Raises $50 Million Series C to Optimize Clinical Research with AI-Powered Digital Twin Technologydcvc.com/press-releases/unlearn-raises-50-million-series-c-to-optimize-clinical-research-with-ai-powered-digital-twin-technology
Unlearn raises $50 million in a Series C round led by Altimeter Capital, with participation from returning investors. The company directs proceeds toward its people, data, engineering, and longer-term research initiatives. Its digital twin models forecast participant outcomes before randomization to enable smaller control arms in clinical trials.
Feb 2024 · DCVCNews article